Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
Date:12/10/2008

- Three Bavituximab Phase II Cancer Trials and the Company's Other Clinical Programs All Advanced During the Quarter -

- Significant Validation Achieved for Bavituximab and Peregrine's Anti-PS Anti-Viral Platform in Nature Medicine Publication -

- Company Enters into Loan Agreement for Up to $10 Million in Funding -

TUSTIN, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the second quarter of fiscal year (FY) 2009 ended October 31, 2008. Separately, the company also announced today that it has entered into a loan agreement for up to $10 million in funding to help finance its ongoing clinical development programs for the treatment of cancer and serious viral infections.

Peregrine reported a consolidated net loss of $4,497,000, or $0.02 per basic and diluted share, compared to a consolidated net loss of $6,207,000, or $0.03 per basic and diluted share for the same prior year period, a decrease of 28%. The net loss decline of $1,710,000 reflects decreased costs in many areas of Peregrine's business, including research and development and selling, general and administrative expenses.

Total revenues for the current quarter were $1,941,000 compared to $1,892,000 for the comparable quarter last year. Revenues were generated from contract manufacturing services provided by Avid Bioservices and from Peregrine's contract with the U.S. Defense Threat Reduction Agency (DTRA) to evaluate bavituximab for the treatment of viral hemorrhagic fever infections. Contract manufacturing revenues generated by Avid were $983,000 for the current quarter compared to $1,863,000 for the comparable prior year quarter. This decrease in Avid revenues is primarily due to the timing of product shipments to customers,
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
2. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
4. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
6. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
7. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
8. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
9. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
10. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
11. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 2013 In honor of women everywhere, ... providing information that women can use to improve their ... women should pay close attention to their health, as ... changes a woman’s body undergoes while pregnant can increase ... says Dr. Ray Workman, a leading vein doctor at ...
(Date:6/19/2013)... Washington, DC (PRWEB) June 19, 2013 ... experiment in the history of managed care. As ... find coverage through the new state-based and federally ... requirements for essential health benefits, and examples of ... some states, industry-leading health business information publisher Atlantic ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Scott Tischler of ... curb this swim suit season. , 1.    The very first thing ... big tall glass of ice cold water. The body is ... water. This will keep the body hydrated and will also ... body has to raise the temperature of the water to ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 As Mirena ... LLP highlights a recent news story from an NBC ... effects of the hormone-based contraceptive device. The Rottenstein Law ... to file Mirena lawsuits and who are ... The U.S. Food and Drug Administration has logged more ...
(Date:6/19/2013)... Transvaginal mesh lawsuits are moving along in the New ... how to handle evidence in the C.R. Bard lawsuits, specifically ... components removed from patients. The Rottenstein Law Group LLP maintains ... about the device and a guide on how to file ... the medical facilities that currently hold them and are to ...
Breaking Medicine News(10 mins):Health News:Novant Health Vein Specialists Promotes Women’s Health with Social Media Campaign 2Health News:New Special Report Provides Comprehensive Overview of New Health Insurance Exchange Marketplaces 2Health News:Rottenstein Law Group LLP Comments on News Reports of Mirena IUD Side Effects 2Health News:Transvaginal Mesh Lawsuit News: NJ Mesh Consolidation Cases Moving Along, Rottenstein Law Group LLP Reports 2
... regular standards then you would see a shrinking pay check, ... to measure up in five areas, including body mass and ... biweekly paycheck if they can't prove to their employer that ... pay $5 extra every two weeks starting in 2008. ...
... of standards among the European Union countries regarding the ... be reduced legal differences between countries that are encouraging ... to people travelling to countries other than their ... or easier to access that over there. According to ...
... places of work is now banned in all of Britain ... bar the habit. ,From 6 am on ... partially enclosed places of work, and most company vehicles have ... still be able to light up outside buildings, in gardens ...
... shifting around body fat to flatten your tummy and ... that ample fat? According to an international study ... ,The study, published online in Nature Medicine, could "revolutionise ... associated with human obesity," the Georgetown University Medical Center ...
... New York on Sunday became the first US city to ... facing an uphill struggle in forcing some eateries to ... majority of New York's 20,000 restaurants, the transition towards healthier ... displayed a degree of reluctance. ,At the heart ...
... superstition and marketing to come together: starry-eyed couples are tying ... as well as the proclamation of the world's seven new ... a magic sacred side and the reputation of bringing luck," ... extra dose of good fortune. ,"Number 7 is ...
Cached Medicine News:Health News:Workers Compelled to Stay in Shape to Avoid Pay Cuts 2Health News:Workers Compelled to Stay in Shape to Avoid Pay Cuts 3Health News:IVF Tourism Marred by Ethical Differences in EU 2Health News:IVF Tourism Marred by Ethical Differences in EU 3Health News:Public Places in England Go Smoke Free 2Health News:Stressed Mice may Hold Clue to How Fat is Stored: Study 2Health News:New York Bans Trans Fats in Restaurants 2Health News:New York Bans Trans Fats in Restaurants 3Health News:A Lucky Number? 7/7/07 2Health News:A Lucky Number? 7/7/07 3
(Date:6/18/2013)... , June 18, 2013  Isis Pharmaceuticals, Inc. (NASDAQ: ... that management will present a general corporate update in conjunction ... on Tuesday, June 25 at 2:10 p.m. Pacific Time in ... for the meeting is as follows: 2:00 p.m. – 2:10 ... as of April 26, 2013) 2:10 p.m. – 3:15 p.m. ...
(Date:6/17/2013)... WASHINGTON , June 17, 2013 ... ) presented additional data today at ENDO 2013, ... demonstrating that tasimelteon can entrain (synchronize) both melatonin ... potential to reset the master body clock and ... Non-24-Hour Disorder (Non-24).  The SET (Safety and Efficacy ...
(Date:6/17/2013)... June 17, 2013 Valeant Pharmaceuticals International, Inc. (NYSE: ... it has filed a preliminary prospectus supplement to its effective ... a similar filing with securities regulatory authorities in each of ... with a public offering of its common shares to raise ... The Company will also grant to the underwriters of the ...
Breaking Medicine Technology:Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4
... collect sample, pipette into testing wells ... FDA 510K cleared multiple drug screen ... both drugs and adulterants. It can ... (5) drugs and can be accompanied ...
... Glucose Monitoring System is a patient insertable short-term ... the DexCom STS Receiver., The DexCom STS Sensor ... the DexCom STS Applicator by the user or ... held in place by an adhesive to the ...
... routine Holter,monitoring, the Burdick Vision ... a,practical, no-nonsense diagnostic tool ideal,for ... This highly accurate and,easy-to-use system ... configurations at a price even ...
... PC-based ECG diagnostics complements transition to ... the incorporation of computer-based technology into ... diagnostic instrumentation have developed. Burdick's Universal ... EMRs making it the ideal choice ...
Medicine Products: